Today

Agents

Chat

Arena

Discover

More

App

AbCellera Biologics receives Jefferies buy rating with $21 price target

ABCL•2026-10-30

Jefferies initiated coverage of AbCellera Biologics with a buy rating and a $21 price target.

Related News

P

PB Financial declares quarterly dividend of $0.65 a share

PBNC•2026-10-30

CenterPoint Energy publishes Q3 2026 earnings call transcript

CNP•2026-10-30

AIG agrees to buy Everest’s Chile insurance business

EG•2026-10-30

Fed's Barkin says US central bank's direction 'straightforward,' question is pace

TLT•2026-10-30

Agility Robotics expects Churchill Capital XI deal to close November 4

CCXI•2026-10-30

AbCellera Biologics receives Jefferies buy rating with $21 price target - ABCL News | Rallies